4-Oxo Cyclophosphamide D8 - Request Quote
4-Oxo Cyclophosphamide D8
| SZ CAT No: | SZ-C072D04 |
| CAS No | NA |
| Mol.F. | C7H5D8Cl2N2O3P |
| Mol.Wt. | 283.1 |
| Inv. Status | Synthesis on demand |
| Rel. CAS No | 27046-19-1 (Unlabeled) |
Chemical Name :
Shipping Temperature :
HSN Code :
Country of Origin :
Smiles :
Usage Note:
4-Oxo Cyclophosphamide D8 is chemically 2-(Bis(2-chloroethyl-1,1,2,2-d4)amino)-1,3,2-oxazaphosphinan-4-one 2-oxide. 4-Oxo Cyclophosphamide D8 is supplied with detailed characterization data compliant with regulatory guideline. 4-Oxo Cyclophosphamide D8 can be used for the analytical method development, method validation (AMV), Quality Controlled (QC) application for Abbreviated New Drug Application (ANDA) or during commercial production of Cyclophosphamide.
The product can be used as reference standards and further traceability against pharmacopeial standards (USP or EP) can be provided based on feasibility. SynZeal products are for analytical purpose only and not for human use.
Applications & Regulatory Use Cases
buy high quality 4-Oxo Cyclophosphamide D8
Purchase 4-Oxo Cyclophosphamide D8
4-Oxo Cyclophosphamide D8 suppliers
4-Oxo Cyclophosphamide D8 manufacturers
4-Oxo Cyclophosphamide D8 price
Order 4-Oxo Cyclophosphamide D8
Enquire 4-Oxo Cyclophosphamide D8
4-Oxo Cyclophosphamide D8 cost
4-Oxo Cyclophosphamide D8 Supplier
4-Oxo Cyclophosphamide D8 Distributor
4-Oxo Cyclophosphamide D8 for Method Validation
Cyclophosphamide Reference Standard
4-Oxo Cyclophosphamide D8 for ANDA Filing
4-Oxo Cyclophosphamide D8 for Forced Degradation Studies
4-Oxo Cyclophosphamide D8 Identification Standards
4-Oxo Cyclophosphamide D8 for DMF Filing
Related Products
Disclaimer
SynZeal product information given on this website is as per the existing understanding while publishing the details on website. The customer is responsible for assessing the accuracy of the information at the time of actual purchase.
SynZeal will update these details as per new developments or findings in product specifications without further notice.


